+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
AAV Gene Therapy Injection Market - Global Forecast 2026-2032- Product Image
AAV Gene Therapy Injection Market - Global Forecast 2026-2032- Product Image
Sale

AAV Gene Therapy Injection Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6145861
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The AAV Gene Therapy Injection Market is projected to reach USD 6.27 Billion in 2026. It is expected to continue growing at a CAGR of 21.66%, reaching USD 20.45 Billion by 2032.

AAV Gene Therapy Injection: Executive Summary

AAV gene therapy injections use adeno-associated virus vectors to deliver genetic payloads to target cells. The field is shaped by advances in molecular design, manufacturing, clinical development, regulatory science, and long-term patient monitoring. Progress depends on demonstrating durable benefit while managing immune responses, vector production complexity, treatment access, and safety obligations.

From Experimental Platforms to Integrated Therapeutic Systems

The landscape is shifting from isolated product development toward integrated capabilities spanning vector engineering, capsid selection, potency testing, process control, cold-chain logistics, and specialized clinical administration. Developers are placing greater emphasis on patient stratification, endpoint selection, durability assessment, and standardized comparability methods. Manufacturing remains a central constraint because production quality, batch consistency, scalability, and analytical characterization directly influence clinical confidence and regulatory review.

Artificial Intelligence Strengthens Discovery, Development, and Operations

Artificial intelligence can support AAV research by identifying relationships among capsid structure, tissue tropism, payload design, and immune recognition. In development, machine-learning tools may assist biomarker selection, patient identification, trial-site planning, imaging interpretation, and adverse-event signal detection. In manufacturing, data-driven monitoring can help identify process deviations and improve analytical workflows. These applications require validated datasets, explainable models, privacy controls, and human oversight; AI does not replace experimental confirmation or regulatory accountability.

Regional Dynamics Across AAV Gene Therapy Development

North America combines advanced biotechnology infrastructure, specialized clinical centers, and experienced regulatory and manufacturing networks. Europe benefits from strong academic collaboration and coordinated scientific capabilities, while the European Union continues to emphasize harmonized regulatory and quality expectations. Asia-Pacific is expanding translational research, manufacturing capacity, and clinical expertise, with Japan, China, South Korea, India, and Australia contributing distinct capabilities. Latin America is developing specialist treatment and research capacity, although access, reimbursement, and logistics remain important considerations. The Middle East is investing in advanced healthcare infrastructure and precision medicine, while Africa faces wider constraints in specialist services, diagnostics, financing, and supply-chain continuity. Regional progress will depend on local training, sustainable procurement, and cross-border evidence generation.

How ASEAN, BRICS, EU, G7, GCC, and NATO Shape the Ecosystem

ASEAN countries can benefit from shared regulatory learning, regional referral pathways, and coordinated specialist training. BRICS members bring diverse research, manufacturing, and healthcare systems, creating opportunities for collaboration while requiring careful alignment of quality and clinical standards. The European Union supports cross-border scientific and regulatory coordination. G7 members contribute substantial research, healthcare, and policy capacity, while also confronting affordability and long-term outcome challenges. GCC states are strengthening advanced-care infrastructure and may serve as regional treatment hubs. NATO members, considered collectively, span mature biomedical ecosystems and diverse national systems; cooperation in health security, supply resilience, and scientific preparedness can support continuity without substituting for civilian regulatory processes.

Country Perspectives on Research, Manufacturing, and Access

The United States has deep capabilities in vector science, clinical development, manufacturing, and regulatory practice. Canada contributes academic research, specialized healthcare, and public-sector scientific capacity. The United Kingdom, France, Germany, Italy, and Spain benefit from established biomedical institutions and European collaboration, with particular attention to health-technology assessment and equitable access. China is strengthening domestic research, manufacturing, and clinical infrastructure, while Japan has advanced regenerative-medicine expertise and a structured regulatory environment. South Korea is developing biotechnology and manufacturing capabilities. Australia combines strong clinical research with geographically dispersed care delivery. India is expanding biotechnology, clinical, and manufacturing capacity, while Brazil and Mexico are building regional expertise amid access and infrastructure considerations. Russia maintains scientific and healthcare capabilities, though international collaboration, supply continuity, and regulatory interoperability affect development conditions.

Priorities for Leaders Building Sustainable AAV Programs

Industry leaders should prioritize manufacturability and analytical control from the earliest design stage, including scalable processes, robust potency assays, and clear comparability strategies. Clinical programs should incorporate immune profiling, meaningful durability endpoints, long-term follow-up, and transparent risk communication. Partnerships with specialist treatment centers can strengthen administration, patient selection, and post-treatment monitoring. Leaders should also establish resilient supply networks, engage regulators and payers early, and design evidence packages that address real-world outcomes and affordability. Responsible AI governance should include model validation, auditability, cybersecurity, and explicit human decision ownership.

Methodology for a Data-Grounded Executive Assessment

This executive summary uses the specified AAV gene therapy injection market scope and synthesizes established industry themes across vector science, clinical development, manufacturing, regulation, healthcare delivery, regional capacity, and technology adoption. Geographic coverage follows the requested regions, groups, and countries. Claims are qualitative and limited to broadly documented structural conditions; no market estimates, market shares, forecasts, or company-specific assessments are included. Interpretation should be supplemented with current regulatory documents, peer-reviewed studies, clinical-trial records, manufacturing guidance, and country-level health-system evidence.

Conclusion: Execution Quality Will Determine AAV Progress

AAV gene therapy injections are advancing within a highly interdisciplinary environment where scientific promise must be matched by manufacturing reliability, clinical durability, safety monitoring, and practical access. Regional and country capabilities are uneven, making collaboration, workforce development, resilient supply chains, and evidence-based policy important. The strongest programs will integrate responsible innovation with rigorous quality systems and patient-centered delivery, allowing the field to progress while maintaining confidence among clinicians, regulators, patients, and healthcare systems.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. AAV Gene Therapy Injection Market, by Indication
7.1. Introduction
7.2. Hemophilia
7.3. Inherited Retinal Disease
7.4. Lysosomal Storage Disorders
7.4.1. Fabry Disease
7.4.2. Gaucher Disease
7.4.3. Pompe Disease
7.5. Neurological Disorders
7.5.1. Parkinson’s Disease
7.5.2. Spinal Muscular Atrophy
8. AAV Gene Therapy Injection Market, by Vector Type
8.1. Introduction
8.2. AAV2
8.3. AAV5
8.4. AAV8
8.5. AAV9
9. AAV Gene Therapy Injection Market, by Delivery Method
9.1. Introduction
9.2. Intramuscular
9.3. Intrathecal
9.4. Intravenous
10. AAV Gene Therapy Injection Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Research Institutes
10.4. Specialty Clinics
11. AAV Gene Therapy Injection Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. AAV Gene Therapy Injection Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. AAV Gene Therapy Injection Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abeona Therapeutics Inc.
15.2. Adverum Biotechnologies Inc.
15.3. Astellas Pharma Inc.
15.4. Biogen Inc.
15.5. BioMarin Pharmaceutical Inc.
15.6. bluebird bio Inc.
15.7. Capsida Biotherapeutics
15.8. CRISPR Therapeutics AG
15.9. CSL Behring LLC
15.10. F. Hoffmann-La Roche Ltd.
15.11. Gilead Sciences Inc.
15.12. Krystal Biotech Inc.
15.13. MeiraGTx Holdings PLC
15.14. Novartis AG
15.15. Pfizer Inc.
15.16. PTC Therapeutics
15.17. REGENXBIO Inc.
15.18. Rocket Pharmaceuticals Inc.
15.19. Sangamo Therapeutics Inc.
15.20. Sarepta Therapeutics Inc.
15.21. Spark Therapeutics Inc.
15.22. Takeda Pharmaceutical Company Limited
15.23. uniQure N.V.
15.24. Voyager Therapeutics Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global AAV Gene Therapy Injection Market, Years Considered for the Study
FIGURE 2. Global AAV Gene Therapy Injection Market, Research Design
FIGURE 3. Global AAV Gene Therapy Injection Market, Research Framework
FIGURE 4. Global AAV Gene Therapy Injection Market, Data Triangulation
FIGURE 5. Global AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
FIGURE 6. Global AAV Gene Therapy Injection Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global AAV Gene Therapy Injection Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global AAV Gene Therapy Injection Market Size, by Vector Type, 2025 vs 2032 (%)
FIGURE 9. Global AAV Gene Therapy Injection Market Size, by Vector Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global AAV Gene Therapy Injection Market Size, by Delivery Method, 2025 vs 2032 (%)
FIGURE 11. Global AAV Gene Therapy Injection Market Size, by Delivery Method, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global AAV Gene Therapy Injection Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global AAV Gene Therapy Injection Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global AAV Gene Therapy Injection Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global AAV Gene Therapy Injection Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global AAV Gene Therapy Injection Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global AAV Gene Therapy Injection Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global AAV Gene Therapy Injection Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global AAV Gene Therapy Injection Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global AAV Gene Therapy Injection Market Segmentation & Coverage
TABLE 2. Global AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 3. Global AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Hemophilia Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Hemophilia Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Hemophilia Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Inherited Retinal Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Inherited Retinal Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Inherited Retinal Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lysosomal Storage Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Lysosomal Storage Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Lysosomal Storage Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Fabry Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Fabry Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Fabry Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Gaucher Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Gaucher Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Gaucher Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Pompe Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Pompe Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Pompe Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Parkinson’s Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Parkinson’s Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Parkinson’s Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Spinal Muscular Atrophy Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Spinal Muscular Atrophy Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Spinal Muscular Atrophy Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 32. Global AAV2 Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global AAV2 Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global AAV2 Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global AAV5 Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global AAV5 Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global AAV5 Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global AAV8 Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global AAV8 Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global AAV8 Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global AAV9 Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global AAV9 Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global AAV9 Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 45. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Intrathecal Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Intrathecal Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Intrathecal Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 72. North America AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. North America AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 74. North America AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 75. North America AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 76. North America AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 77. North America AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 78. North America AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Latin America AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Latin America AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 81. Latin America AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 82. Latin America AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 83. Latin America AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 84. Latin America AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 85. Latin America AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. Europe AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Europe AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 88. Europe AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 89. Europe AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 90. Europe AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 91. Europe AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 92. Europe AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 93. Middle East AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Middle East AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 95. Middle East AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 96. Middle East AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 97. Middle East AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 98. Middle East AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 99. Middle East AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 100. Africa AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Africa AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 102. Africa AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 103. Africa AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 104. Africa AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 105. Africa AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 106. Africa AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. Global AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. ASEAN AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. ASEAN AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 110. ASEAN AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 111. ASEAN AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 112. ASEAN AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 113. ASEAN AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 114. ASEAN AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. GCC AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. GCC AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 117. GCC AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 118. GCC AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 119. GCC AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 120. GCC AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 121. GCC AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. European Union AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. European Union AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 124. European Union AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 125. European Union AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 126. European Union AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 127. European Union AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 128. European Union AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 129. BRICS AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. BRICS AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 131. BRICS AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 132. BRICS AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 133. BRICS AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 134. BRICS AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 135. BRICS AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. G7 AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. G7 AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 138. G7 AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 139. G7 AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 140. G7 AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 141. G7 AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 142. G7 AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. NATO AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. NATO AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 145. NATO AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 146. NATO AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 147. NATO AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 148. NATO AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 149. NATO AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. Global AAV Gene Therapy Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 151. United States AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 152. United States AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 153. United States AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 154. United States AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 155. United States AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 156. United States AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 157. United States AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. Canada AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 159. Canada AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 160. Canada AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 161. Canada AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 162. Canada AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 163. Canada AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 164. Canada AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 165. Mexico AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 166. Mexico AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. Mexico AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 168. Mexico AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 169. Mexico AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 170. Mexico AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 171. Mexico AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. Brazil AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 173. Brazil AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 174. Brazil AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 175. Brazil AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 176. Brazil AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 177. Brazil AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 178. Brazil AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. United Kingdom AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 180. United Kingdom AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 181. United Kingdom AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 182. United Kingdom AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 183. United Kingdom AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 184. United Kingdom AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 185. United Kingdom AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 186. Germany AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 187. Germany AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. Germany AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 189. Germany AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 190. Germany AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 191. Germany AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 192. Germany AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. France AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 194. France AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 195. France AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 196. France AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 197. France AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 198. France AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 199. France AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. Russia AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 201. Russia AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 202. Russia AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 203. Russia AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 204. Russia AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 205. Russia AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 206. Russia AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. Italy AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 208. Italy AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 209. Italy AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 210. Italy AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 211. Italy AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 212. Italy AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 213. Italy AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. Spain AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 215. Spain AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 216. Spain AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 217. Spain AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 218. Spain AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 219. Spain AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 220. Spain AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. China AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 222. China AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 223. China AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 224. China AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 225. China AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 226. China AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 227. China AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 228. India AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 229. India AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 230. India AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 231. India AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 232. India AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 233. India AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 234. India AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. Japan AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 236. Japan AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 237. Japan AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 238. Japan AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 239. Japan AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 240. Japan AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 241. Japan AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 242. Australia AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 243. Australia AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 244. Australia AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 245. Australia AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 246. Australia AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 247. Australia AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 248. Australia AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 249. South Korea AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
TABLE 250. South Korea AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
TABLE 251. South Korea AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
TABLE 252. South Korea AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 253. South Korea AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
TABLE 254. South Korea AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 255. South Korea AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. Global AAV Gene Therapy Injection Market Share, by Key Player, 2025
TABLE 257. Global AAV Gene Therapy Injection Market, Key Experts

Companies Mentioned

  • Abeona Therapeutics Inc.
  • Adverum Biotechnologies Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio Inc.
  • Capsida Biotherapeutics
  • CRISPR Therapeutics AG
  • CSL Behring LLC
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Krystal Biotech Inc.
  • MeiraGTx Holdings PLC
  • Novartis AG
  • Pfizer Inc.
  • PTC Therapeutics
  • REGENXBIO Inc.
  • Rocket Pharmaceuticals Inc.
  • Sangamo Therapeutics Inc.
  • Sarepta Therapeutics Inc.
  • Spark Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • uniQure N.V.
  • Voyager Therapeutics Inc.

Related Topics

Related Reports

Ophthalmic AAV Gene Therapy Market - Global Forecast 2026-2032 - Product Image

Ophthalmic AAV Gene Therapy Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Gene Therapies in Ophthalmology - Competitive Landscape, 2026 - Product Image

Gene Therapies in Ophthalmology - Competitive Landscape, 2026

  • Report
  • 280 Pages
  • Global
From
AAV Gene Therapy Drugs Market - Global Forecast 2026-2032 - Product Image

AAV Gene Therapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Gene Therapy - Competitive Landscape, 2026 - Product Image

Gene Therapy - Competitive Landscape, 2026

  • Report
  • 550 Pages
  • Global
From
AAV Gene Therapy Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

AAV Gene Therapy Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.